INFLAMMATION IS AN ESSENTIAL component of host defense against harmful stimuli, involving a complex interplay between vascular tissues and blood leukocytes. Leukocyte recruitment to sites of inflammation occurs via a series of molecular and cellular events, beginning with the tethering and rolling of leukocytes on the endothelium lining blood vessels, followed by firm arrest, diapedesis, and finally leading to extravasation into the vascular wall (31) . These cellular responses are accompanied by changes in the expression of effector molecules such as surface adhesion proteins, receptors and mediators secreted by the endothelium and recognized by neutrophils (41) . Therefore, the efficacy of neutrophils in reaching infected tissues is dependent on recognizing and responding to alterations of endothelial functions. Interestingly, many of the mediators that neutrophils respond to are also extensively involved in angiogenesis, a phenomenon that leads to the formation of new blood vessels from preexisting vasculature. Factors such as vascular endothelial growth factor (VEGF), angiopoietins (Ang1, Ang2), and interleukins (IL)-1, -6, and -8, all of which are extensively involved at different stages of angiogenesis, have been shown to modulate neutrophil survival, degranulation, respiratory burst, adhesion, and chemotaxis (5, 11, 28, 32, 36) .
Another set of potent angiogenic modulators, the family of fibroblast growth factors (FGFs), is also involved in the inflammatory process, but the contribution of specific FGFs to different stages of inflammation remains to be elucidated. Evidence of the involvement of FGFs in inflammation comes from observations that the two most studied members of the family, FGF-1 and FGF-2, are upregulated in inflammatory disorders such as bowel syndrome, Crohn's disease, ulcerative colitis (23) , and rheumatoid arthritis (6) . Other reports have suggested that FGF-1 and FGF-2 are secreted by and may act as immunoregulators of infiltrating neutrophils, monocytes, macrophages, and T lymphocytes, often in tandem with powerful inflammatory cytokines (3, 7, 33) . The notion that FGF-2 alters neutrophil behavior secondary to the activation of endothelial cells (ECs) rather than through direct interaction is supported by evidence that FGF-2 enhances EC surface expression of adhesion molecules ICAM-1/2 (51), E-selectin (34) , and monocyte chemoattractant protein-1 (33, 42, 49) before neutrophil rolling and adhesion. Although one study showed that FGF-2 primes neutrophil respiratory burst and increases their surface expression of integrins CD11b/CD18 (42) , the effects of direct FGF stimulation, especially those of FGF-1, on neutrophil biological activities remain largely unexplored.
In general, the effects of FGFs, of which there are 23 members, are mediated by binding to four high-affinity tyrosine kinase receptors (FGFR1-4) and their splice variants (22) . The diversity in FGF signaling is due, in part, to different FGF/FGFR combinations. Additionally, alternative splicing in the FGFR immunoglobulin (Ig)-like domains generates additional receptor isoforms with novel ligand affinities. Finally, effector cells will usually express different heparan-sulfates at their surface, which are responsible for stabilizing FGF/FGFR complexes and enhancing FGFR downstream signaling (10, 46) .
Although it has been shown that cells of hematopoietic origin express functional FGFRs (1), no information has been reported regarding the receptors that mediate the effects of FGF-1 and FGF-2 in neutrophils. Therefore, the aim of the present study was to determine whether neutrophils expressed FGFRs and if so, to characterize the contribution of the identified FGFRs to the effects of FGF-1 and FGF-2 on neutrophil chemotaxis.
MATERIALS AND METHODS
Neutrophil purification. Venous blood samples were obtained from healthy donors free from medication for at least 10 days before the start of the experiments. The study has been approved by the human ethical committee of the Montreal Heart Institute, and all subjects provided written informed consent. Neutrophils were isolated using Ficoll-Hypaque gradient, as described previously (32, 36, 44) , and resuspended in RPMI medium (Lonza, Allendale, NJ) supplemented with 25 mM HEPES (N-2-hydroxyethylpiperazine-N=-2-ethanesulfonic acid) and 1% penicillin-streptomycin. Ninety-eight (98) percent of the isolated cells were polymorphonuclear cells, as determined with a Coulter counter, and viability was found to be Ͼ98%, as assessed by Trypan blue dye exclusion assay.
FGF receptor identification by quantitative RT-PCR analyses. Total RNAs were obtained from freshly isolated human neutrophils (10 7 cells) by using the RNeasy extraction kit (Qiagen, Mississauga, ON, Canada). Total RNAs (100 ng) was reverse transcribed using random hexamers and the Moloney murine leukemia virus (MMLV) reverse transcriptase (Invitrogen, Burlington, ON, Canada) as described by the manufacturer. Reactions were performed on a MX3500P (Stratagene, La Jolla, CA) using 10 ng of cDNAs, Syber Green (Invitrogen), and 300 nM of the primers (Table 1) for each receptor. cDNAs were submitted to 45 cycles of amplification (temperatures for annealing: 60°C; dissociation: 55°C) and gave single peaks for each product.
Reverse transcriptase polymerase chain reaction [quantitative RT-PCR (RT-qPCR)] products were purified on a 2% acrylamide gel, quantified using QIAquick Gel Extraction Kit (Qiagen), and sequenced (Genome Quebec Innovation Centre, McGill University, Montreal, QC, Canada). The concentration of the purified products was measured using a NanoDrop spectrophotometer, and eluted amplicons were used in another set of RT-qPCR reactions as serial dilutions to generate standard curves for each set of oligonucleotides. The number of copies was calculated using the following formula: number of copies ϭ [amount (ng) ϫ 6.022 ϫ 10 23 ]/[length (bp) ϫ 1 ϫ 10 9 ϫ 650 (g/mol of bp)]. Standard curves of cDNA copies were generated by RT-qPCR and used to determine the number of mRNA copies for each receptor.
Immunohistochemistry. Freshly isolated human neutrophils (1.2 ϫ 10 8 cells) were centrifuged, and the pellet was fixed in 10% PBSbuffered formalin overnight, dehydrated in a graded series of ethanol solutions and xylene, and embedded in paraffin. Sections 6 m thick were rehydrated, blocked in 10% normal goat serum (NGS), and incubated overnight with rabbit polyclonal anti-human FGFR1-4 IgG or normal rabbit IgG (1:200 dilution; Santa Cruz Biotechnology, Santa Cruz, CA). Following a 30-min incubation with the secondary antibody (goat anti-rabbit IgG, 1% NGS), sections were rinsed three times in Tris buffer and incubated in Vectastain ABC alkaline phosphatase solution (Vector, Burlington, ON, Canada) and revealed with the Vector black alkaline phosphatase substrate solution for 30 min each as recommended by the manufacturer. Slices were rinsed, immerged in methyl green (10 min, 60°C), dehydrated, mounted with resinous medium, and examined with a light microscope under ϫ400 and ϫ1,000 magnification. No cross-reactivity was observed between FGFR1-4 antibodies.
Confocal microscopy. Neutrophils were isolated as aforementioned, allowed to adhere on glass coverslips precoated with poly-Llysine (BD BioCoat; Becton Dickinson, Mississauga, ON, Canada) for 1 h, and fixed with a 2% paraformaldehyde solution. Nonspecific binding of primary antibodies was prevented by preincubating fixed neutrophils with 10% serum from the species used to raise secondary antibodies. Neutrophils were exposed to mouse monoclonal antihuman FGFR1-4 IgG (R&D Systems, Minneapolis, MN) and to a secondary goat anti-mouse antibody coupled to the Cy3-fluorochrome (Invitrogen). No cross-reactivity was observed between FGFR1-4 antibodies. Neutrophil preparations were mounted using DABCO (1,4-diazabicyclo-2-2-2-octane)/glycerol (1:1) solution and glass coverslip. Stained neutrophils were observed by confocal microscopy [Zeiss Axiovert 100 M microscope equipped with a ϫ63/1.4 PlanApochromat oil objective lens (Zeiss, Oberkochen, Germany) and adapted with an LSM 510 confocal system]. Images were recorded with LSM 510 software (Zeiss) and exported in tagged-image file format (TIFF).
Flow cytometry (FACS). Neutrophils (10 7 cells/ml) were rinsed and resuspended in RPMI, and mouse IgG (150 g/ml) was added for 30 min to prevent nonspecific binding via Fc receptors. Neutrophils were centrifuged, rinsed, resuspended in PBS-BSA (10 6 cells/ml, 1% BSA), and incubated with phycoerythrin (PE)-conjugated mouse monoclonal anti-human FGFR1-4 IgG (25 or 50 g/ml, R&D Systems), or with control PE-conjugated mouse monoclonal IgG1 (50 g/ml, R&D Systems) for 30 min at room temperature. Cells were rinsed and fixed with 2% paraformaldehyde. Flow cytometric analysis (10 5 events) was performed using a FACScan (Becton Dickinson, San Jose, CA).
Neutrophil migration. In vitro chemotactic assays were performed in a 48-well modified Boyden chamber apparatus (Neuro Probe, Gaithersburg, MD) as previously described (5, 26) . Briefly, the bottom wells were loaded with RPMI containing PBS, IL-8 (25 nM), FGF-1 (10 Ϫ14 to 10 Ϫ8 M), or FGF-2 (10 Ϫ14 to 10 Ϫ8 M) to a final volume of 27 l. The top wells were loaded with neutrophils (10 6 cells/ml; 50 l from a RPMI suspension). The top and bottom wells were separated by a porous polycarbonate membrane filter (3-m pore size). The modified Boyden chamber apparatus was incubated at 37°C for 1 h in a humidified incubator in the presence of 5% CO 2. At the end of the incubation period, the upper part of the modified Boyden chamber (upper wells) was removed, and the upper side of the polycarbonate membrane was wiped carefully with the rubber scraper provided by the manufacturer. The polycarbonate membrane was In another set of experiments, neutrophils were pretreated with 0.1 g/ml of blocking anti-FGFR-1, FGFR-2, or FGFR-4 antibodies (R&D Systems) or with an isotype-matched control IgG for 30 min before a 1-h migration toward PBS, IL-8 (25 nM), FGF-1 (10 Ϫ9 M), or FGF-2 (10 Ϫ9 M). In the latter experiment, maximal effect was set to 100% and corresponds to the number of IgG-pretreated neutrophils migrating toward FGF-1 or FGF-2. The migration of neutrophils pretreated with FGFR antibodies was expressed as a percentage of the maximum FGF-induced response in absence of FGFR antibodies.
Statistical analysis. Data are presented as means Ϯ SE. Statistical comparisons were made by Student's t-test or by a one-way analysis of variance, followed by Tukey post hoc where applicable using GraphPad Prism (Mac version 5.0b). Differences were considered significant at P Ͻ 0.05.
RESULTS
Neutrophil expression of FGFR mRNA. Using neutrophils isolated from venous blood samples of 22 healthy volunteers, we determined the mRNA expression of FGF receptors (1 to 4; FGFR1-4), as described in MATERIALS AND METHODS. Neutrophils expressed an average of 4.72 ϫ 10 5 copies of total FGFR mRNA, irrespective of the subtypes. FGFR-2 mRNA had the highest level of expression (3.10 Ϯ 0.67 ϫ 10 5 mRNA copies) followed by FGFR-4 (1.07 Ϯ 0.24 ϫ 10 5 copies) and FGFR-1 (0.6 Ϯ 0.12 ϫ 10 5 copies), whereas FGFR-3 mRNA level was undetectable (Fig. 1A) . As the levels of total FGFR mRNA copies varied between individuals, we represented the distribution of each of FGFR1-4 mRNA per donor. We arbitrarily separated the donors into low (Ͻ4 ϫ 10 5 copies; 11/22 donors) and high expressers (Ͼ4 ϫ 10 5 copies; 11/22 donors) (Fig.  1B) ; regardless of which group the donors belonged to, FGFR-2 represented the highest proportion of total FGFR mRNA, corresponding to 51.0 Ϯ 9.5% and 67.9 Ϯ 5.1% of the total FGFR mRNA for low and high expressers (Fig. 1C) .
Neutrophil expression and localization of FGFR proteins. Independently of the above mRNA analyses, neutrophils from 16 different donors were examined for FGFR1-4 protein expression and localization by conventional immunohistochemistry (IHC). Because of the variations in staining intensities and the number of cells that were marked between different donors, we distinguished four staining patterns (Fig. 2, A-E) to which we attributed qualitative scores: score 0 (background staining; Fig. 2A ), score 1 (faint but detectable staining in some cells; Fig. 2E ), score 2 (high staining in some cells; Fig. 2B ), or score 3 (high staining in most cells; Fig. 2C ). The staining scores for each donor, along with the means of the scores for comparative purposes, are presented in Table 2 . FGFR-1 staining showed high staining on a small subset of the neutrophils for most donors (Fig. 2B) . The majority of donors scored high for FGFR-2, with a much larger fraction of neutrophils intensely stained (Fig. 2C) . FGFR-3 and FGFR-4 expression fell between scores 0 and 1 as most donors showed either very faint staining in a minor population of neutrophils or no detection at all (Fig. 2, D and E) . We also observed differences in the localization of the staining, especially between FGFR-2 and FGFR-1 (and to a lesser extent FGFR-4), as shown by the boxed, magnified images in Fig. 2 . When viewed at ϫ1,000 magnification, neutrophils stained for FGFR-2 showed a distinct darker coloration at the cytoplasmic periphery, unlike FGFR-1 or FGFR-4, which showed a rather diffuse intracellular staining pattern. These observations suggest that FGFR-2 is the only neutrophil cell surface receptor, whereas FGFR-1 and FGFR-4 show a cytosolic localization.
Data obtained from flow cytometry analyses reflected the same variability in expression levels of FGFR1-4 from one donor to another. By confocal microscopy, we determined whether the receptors were localized intracellularly or at the cell surface. We observed that FGFR-1 and FGFR-4 staining was perinuclear and diffused across the cytosol of the neutrophils, whereas FGFR-2 staining was mainly confined to a thin strip in close proximity to the cell surface. Once again, FGFR-3 detection was similar to the nonspecific IgG background (Fig. 3) .
Characterization of FGFR-2. FGF receptors share the same basic protein structure, which is characterized by up to three extracellular Ig domains (denoted by Ig-I, -II, or -III). These Ig domains define the affinity and responsiveness of FGFRs for different FGF ligands (10, 18, 29) . In normal tissues, FGFRs express all three Ig domains and are referred to as "FGFR-␣" (Fig. 4A) . The loss of Ig-I gives rise to "short" forms of FGFRs called "FGFR-␤," correlating with transformation to a malignant phenotype and invasiveness (24, 48) . FGFR-␤ forms are thus found in cancerous cell lines, having a 1,000-fold higher affinity to FGF-1 but not for FGF-2. The complexity of the FGFR family is increased by alternative splicing in exons 9 or 8 of Ig-III domain, generating FGFR-IIIb and FGFR-IIIc isoforms, respectively (Fig. 4B) . These splicing events confer additional ligand-binding properties to FGFRs (45) .
Because we identified FGFR-2 as the only cell surface receptor, we further characterized the expression of its different isoforms. We looked at the FGFR-2 mRNA transcript, first to establish whether all three Ig domains were coded, and second to determine which of exons IIIb or IIIc in Ig-III were spliced. As per our previous experiments, we performed RTqPCR analyses and determined that FGFR-2␣ is nearly the exclusive isoform (Fig. 4C) . We then quantified the mRNA of both FGFR-2␣-IIIb and FGFR-2␣-IIIc subtypes and observed that, in neutrophils, FGFR-2 mRNA was primarily FGFR-2␣-IIIc. (51, 52) . However, the possibility that FGFs could be direct stimulators of leukocyte recruitment was not addressed. To this end, we used a modified Boyden microchamber model and observed that both FGF-1 and FGF-2 were capable of mediating neutrophil chemotaxis at picomolar concentrations. In addition, treatment with FGF-1 or FGF-2 (10 Ϫ14 to 10 Ϫ8 M) induced a bell-shape response on the number of migrating neutrophils as compared with control PBS-treated cells. The maximal effect was achieved at 10 Ϫ10 M for FGF-1 and 10
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M for FGF-2, corresponding to 1.77-and 2.34-fold increase over PBS-mediated neutrophil migration, respectively. The positive control IL-8 (25 nM) increased migration by 2.72-fold as compared with control PBS-treated neutrophils (Fig. 5A) .
In another set of experiments, we assessed the contribution of FGFR-1, FGFR-2 and FGFR-4 to FGF-mediated che- whereas anti-FGFR-1 and FGFR-4 antibodies reduced migration by 28.9% and 14.6%, respectively (Fig. 5B) . In contrast, basal and IL-8-induced neutrophil migration was unaffected in the presence of anti-FGFR antibodies (data not shown).
DISCUSSION
In the current study, we demonstrate that circulating neutrophils isolated from the blood of healthy individuals express varying levels of FGFR-1, -2, and -4 mRNA, with FGFR-2 mRNA showing the most consistent and highest level of expression. At the protein level, donors showed a heterogeneous expression of FGF receptors. We identified FGFR-2 as the most expressed and unique neutrophil cell surface receptor, whereas FGFR-1 and FGFR-4 appeared to be cytosol bound. Neither the mRNA nor the protein for FGFR-3 was significantly detectable. In addition, we observed that FGF-1 and FGF-2 were capable of stimulating neutrophil migration under in vitro conditions, mainly through FGFR-2 activation.
FGF-1 and FGF-2 are potent heparin-binding proangiogenic growth factors that exert their biological functions through the activation of high affinity tyrosine kinase receptors (FGFRs), heparan-sulfate proteoglycans (HSPGs) and integrins expressed on the surface of effector cells (17) . Although the presence of FGFRs on human neutrophils has not been reported, these leukocytes from a biological standpoint seem naturally well equipped to respond to FGF stimulation. First, neutrophils express integrins as well as HSPGs, accessory coreceptors that facilitate dimerization of tyrosine kinase receptors and amplify the signaling triggered by HSPG-binding growth factors such as FGFs. Second, neutrophils present at their surface the receptors for at least two other families of angiogenic growth factors with similar properties to FGFs. Indeed, neutrophils were shown to express VEGF receptor-1 and Tie2, which are responsible for VEGF and Ang-mediated neutrophil chemotaxis, respectively (2, 26) .
Detection and localization of FGF receptors in human neutrophils. The initial objective of our study was to determine whether neutrophils expressed FGF receptors. Quantitative RT-PCR analyses showed a trend among individuals to express more mRNA for FGFR-2 than any of the other FGF receptor 1  2  3  1  2  2  3  1  0  1  3  1  3  0  0  4  0  0  0  0  5  1  3  0  2  6  3  3  1  2  7  1  2  0  1  8  0  2  0  1  9  2  2  0  0  10  2  2  0  1  11  3  2  0  1  12  1  2  0  1  13  0  2  1  0  14  1  2  1  0  15  1  1  1  0  16  2  2 subtypes. FGFR-1 and FGFR-4 mRNA were also detectable with a generally lower number of copies, whereas FGFR-3 was minimally or not detected. Owing to the fact that the presence of the mRNA does not always coincide with the expression of its corresponding protein, we examined FGFR protein expression by immunostaining and confocal microscopy. FGFR-2 was detected on a large subset of neutrophils for many of the donors, with a staining pattern to the cell surface membrane. FGFR-1 and FGFR-4 showed a less intense but uniformly diffused staining across the cytoplasm of a small fraction of neutrophils, suggesting that if these receptors were indeed cytoplasmic, they were not confined to specific subcellular fractions or to vesicles. FGFR-3 protein detection was absent to very low, in accordance with its corresponding mRNA levels. Fig. 3 . Localization of FGFR1-4 by confocal microscopy. Human neutrophils were stained with specific anti-human FGFR1-4 antibodies and a secondary Cy3-coupled antibody. Labeled neutrophils were viewed under confocal microscope to assess the protein localization of FGFR1-4. Columns, left to right, correspond to images of neutrophils taken from random fields: phase contrast showing membrane integrity, specific FGFR staining (secondary antibody coupled to Cy3 dye), and nuclear counterstaining (To-pro). The three-dimensional reconstructions of confocal Z-stack images (last column) correspond to neutrophils chosen at random from the larger associated fields.
Characterization of FGFR-2.
The specificity of the FGFneutrophil interaction is determined not only on the basis of which FGFR is expressed at the cell surface, but also by the subtype and isoform of the surface receptor. Most mammalian FGFRs exist as the FGFR-␣ isoform, which consists of three extracellular immunoglobulin-like domains (Ig I-III). The lack of Ig-I, which gives rise to short forms of FGFR called "␤," leads to a 1,000-fold increase in FGF-1 responsiveness and an important reduction in FGF-2 affinity. FGFs interact with the Ig-II and Ig-III domains, with the Ig-III interactions primarily responsible for ligand-binding specificity. Alternative splicing of exons 9 and 8 in the Ig-III domain gives rise to "IIIb" and "IIIc" variants for FGFR-1, -2, and -3, thus generating seven possible FGFR subtypes at the cell surface that bind a specific subset of FGFs. FGF-1 is capable of activating all seven FGFRs. In contrast, FGF-2 only binds the IIIc forms of FGFRs (9, 10, 14, 15, 20 -22, 30) . Using qPCR analysis, we confirmed that nearly all the FGFR-2 mRNA from human neutrophils comprises all three Ig domains, coding for the ␣-isoform. Furthermore, the majority of the FGFR-2 mRNA contains exon 9 in the second part of Ig-III domain, which would thereby generate IIIc isoforms. The presence of FGFR-2␣-IIIc isoform on the cell surface of human neutrophils would allow them to interact with FGF-1, FGF-2, FGF-4, and FGF-6 but not with FGF-3, FGF-7, or FGF-10 (4, 14, 29) . Given the role of FGFs in angiogenesis, this finding could potentially have important physiological implications; indeed, in cases such as following a cerebral stroke or cardiac ischemia, where an increase in angiogenesis is desired to improve reperfusion while maintaining a minimal influx of inflammatory cells, the choice of FGF ligand could become critical.
Our data regarding FGFR1-4 protein expression and localization are in agreement with previous studies reporting the presence of soluble cytosolic forms for FGF receptors in blood and different cell types (18, 37) . The function of the cytoplasmic FGFRs can only be speculative at the moment, but we did consider the possibility that FGF-2 could induce the translocation of its own receptors from the cytosol of the neutrophils to the cell surface. However, when neutrophils were treated with FGF-2 for up to 24 h, FGFR1-4 detection was not significantly increased, as measured by flow cytometry (data not shown). Nevertheless, this observation does not exclude the possibility that FGFR1-4 translocation could be induced by other more potent inflammatory mediators such as IL-8, TNF-␣, or bacterial lipopolysaccharide (LPS), all of which can promote protein translocation to the surface of neutrophils (12, 36) . It is possible that the soluble forms of FGFR-1 and -4 are proteolytically cleaved by matrix metalloproteases (MMPs) inside the cell before they reach the cytoplasmic membrane, especially since neutrophils synthesize, store, and release large amounts of MMP-2 (13) and MMP-9 (19, 40) . This proteolysis can occur in different locations within the cell, especially since MMPs have been shown to cleave substrates in nuclear, mitochondrial, cytoplasmic, and vesicular compartments, including the intracellular cytoskeletal matrix (8) . Furthermore, the presence of FGF-2 in the cytoplasm of neutrophils has been reported (35) , which raises the possibility that FGF-2 could have undetermined intracellular functions and could be sequestered by soluble FGFR proteins. Further experimentation will be required before a functional role for these cytoplasmic receptors can be ascertained.
FGF-1 and FGF-2-mediated chemotaxis. Numerous angiogenic factors have been shown to modulate leukocyte behavior under inflammatory conditions. For instance, VEGF has been reported to promote several chronic inflammatory disorders (16, 25, 27, 38, 39, 43, 50) . It has been shown that FGF-2 can modulate the interaction of leukocytes with ECs in vitro (6, 47, 51) , secondary to the stimulation of adhesion molecule expression on ECs. We addressed the capacity of FGF-1 and FGF-2 to directly modulate neutrophil chemotaxis in an EC-free environment by using a modified Boyden microchamber model. We observed that both FGF-1 and FGF-2 were capable of stimulating neutrophil recruitment, albeit with different potencies. These effects were almost completely abrogated with blocking anti-FGFR-2 antibodies, and only partially blocked by anti-FGFR-1 and FGFR-4 antibodies, suggesting that most of the chemotactic activities of FGFs are mediated by FGFR-2 activation.
In summary, our results demonstrate for the first time the exclusive expression of FGFR-2 at the surface of human neutrophils. The predominance of the FGFR-2␣-IIIc isoform suggests that neutrophils respond to only a specific subset of FGF ligands. Accordingly, we observed that FGF-1 and FGF-2, both of which bind strongly to FGFR-2␣-IIIc, act as chemotactic agents for the recruitment of neutrophils in vitro, mainly through direct interaction and activation of FGFR-2. Consequently, this study delineates a key inflammatory role for FGF-1 and FGF-2 and supports the possibility of additional functions for FGF/FGFR complex in modulating polymorphonuclear leukocyte proinflammatory activities.
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